Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor

Author:  ["Yvonne P. Tretter","Moritz Hertel","Barbara Munz","Gerrit ten Bruggencate","Sabine Werner","Christian Alzheimer"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Exogenous application of neurotrophic growth factors has emerged as a new and particularly promising approach not only to promote functional recovery after acute brain injury but also to protect neurons against the immediate effect of the injury. Among the various growth factors and cytokines studied so far, the neuroprotective and neurotrophic profile of basic fibroblast growth factor (bFGF) is the best documented1,2,3,4,5. Using an animal model of acute excitotoxic brain injury6, we report here that the neuroprotective action of bFGF, which is now being tested in stroke patients, depends on the induction of activin A, a member of the transforming growth factor-β superfamily. Our evidence for this previously unknown mechanism of action of bFGF is that bFGF strongly enhanced lesion-associated induction of activin A; in the presence of the activin-neutralizing protein follistatin, bFGF was no longer capable of rescuing neurons from excitotoxic death; and recombinant activin A exerted a neuroprotective effect by itself. Our data indicate that the development of substances influencing activin expression or receptor binding should offer new ways to fight neuronal loss in ischemic and traumatic brain injury.

Cite this article

Tretter, Y., Hertel, M., Munz, B. et al. Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo. Nat Med 6, 812–815 (2000). https://doi.org/10.1038/77548

View full text

>> Full Text:   Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after disc

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic viru